Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Robinson

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
The American Journal of Gastroenterology|August 27, 2014
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3Jean-Frederic Colombel, William J Sandborn, Subrata Ghosh, et al.
Intestinal Research|May 14, 2016
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's diseaseKai-Chun Wu, Zhi Hua Ran, Xiang Gao, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADASimon Travis, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2014
Adalimumab for the treatment of Japanese patients with intestinal Behçet's diseaseSatoshi Tanida, Nagamu Inoue, Kiyonori Kobayashi, et al.
The American Journal of Gastroenterology|January 11, 2017
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's DiseaseReena Khanna, GuangYong Zou, Larry Stitt, et al.
The American Journal of Gastroenterology|April 19, 2017
Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's DiseaseReena Khanna, GuangYong Zou, Larry Stitt, et al.
Lancet (London, England)|November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialJean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
The Lancet. Gastroenterology & Hepatology|July 30, 2018
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension studyBrian G Feagan, Julián Panés, Marc Ferrante, et al.
Gastroenterology|February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial ResultsGeert R D'Haens, William J Sandborn, Edward V Loftus, et al.
Gastroenterology|March 1, 2022
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial ResultsJulián Panés, Jean-Frederic Colombel, Geert R D'Haens, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
The American Journal of Gastroenterology|August 27, 2014
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3Jean-Frederic Colombel, William J Sandborn, Subrata Ghosh, et al.
Intestinal Research|May 14, 2016
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's diseaseKai-Chun Wu, Zhi Hua Ran, Xiang Gao, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADASimon Travis, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2014
Adalimumab for the treatment of Japanese patients with intestinal Behçet's diseaseSatoshi Tanida, Nagamu Inoue, Kiyonori Kobayashi, et al.
The American Journal of Gastroenterology|January 11, 2017
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's DiseaseReena Khanna, GuangYong Zou, Larry Stitt, et al.
The American Journal of Gastroenterology|April 19, 2017
Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's DiseaseReena Khanna, GuangYong Zou, Larry Stitt, et al.
Lancet (London, England)|November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialJean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
The Lancet. Gastroenterology & Hepatology|July 30, 2018
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension studyBrian G Feagan, Julián Panés, Marc Ferrante, et al.
Gastroenterology|February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial ResultsGeert R D'Haens, William J Sandborn, Edward V Loftus, et al.
Gastroenterology|March 1, 2022
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial ResultsJulián Panés, Jean-Frederic Colombel, Geert R D'Haens, et al.
Pageof 5